---
title: "JINYU's subsidiary has obtained a new veterinary drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252984115.md"
description: "The wholly-owned subsidiary of JINYU, Yangzhou Youbang Biopharmaceutical Co., Ltd., and Jinyu Baoling Biopharmaceutical Co., Ltd. jointly developed the inactivated vaccine for porcine parvovirus vector (rPP03 strain), which has obtained a new veterinary drug registration certificate. This move reflects the company's emphasis on research and development innovation, enriches the product line of vaccines for pigs, and enhances market competitiveness and sustainable development capabilities"
datetime: "2025-08-14T07:39:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252984115.md)
  - [en](https://longbridge.com/en/news/252984115.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252984115.md)
---

# JINYU's subsidiary has obtained a new veterinary drug registration certificate

According to the announcement from Zhitong Finance APP, JINYU (600201.SH) has released a notice stating that, in accordance with the national "Regulations on Veterinary Drugs" and "Veterinary Drug Registration Measures," the company's wholly-owned subsidiary Yangzhou Youbang Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Yangzhou Youbang"), Jinyu Baoling Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinyu Baoling"), and other companies have jointly developed the inactivated vaccine for porcine parvovirus vector (rPP03 strain) as a new veterinary drug, approved by the Ministry of Agriculture and Rural Affairs of the People's Republic of China.

The successful approval of this product reflects the company's continuous emphasis on research and development innovation and the ongoing enrichment of its product pipeline. It further enriches the company's matrix of porcine vaccine products. After years of accumulation, the company has a rich product reserve in the field of porcine vaccines, which can meet the diversified market demands and provide multi-dimensional comprehensive epidemic prevention solutions for downstream breeding customers, consolidating the company's industry position in the field of animal vaccines. This has a positive promoting effect on enhancing the company's research and development capabilities, market competitiveness, and sustainable development

### Related Stocks

- [600201.CN](https://longbridge.com/en/quote/600201.CN.md)

## Related News & Research

- [ZAWYA: Kia’s global partner, The Ocean Cleanup expands plastic interception project ahead of LA28](https://longbridge.com/en/news/287182378.md)
- [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)